Soheila Korourian
Concepts (303)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 30 | 2018 | 1200 | 2.700 |
Why?
| Carcinoma, Ductal, Breast | 9 | 2015 | 96 | 1.800 |
Why?
| Mastectomy, Segmental | 8 | 2015 | 94 | 1.490 |
Why?
| Catheter Ablation | 4 | 2014 | 136 | 1.260 |
Why?
| Neoplasm Recurrence, Local | 7 | 2014 | 576 | 1.200 |
Why?
| Sentinel Lymph Node Biopsy | 15 | 2017 | 120 | 1.190 |
Why?
| Mastectomy | 10 | 2018 | 139 | 1.140 |
Why?
| Mammary Neoplasms, Experimental | 7 | 2010 | 146 | 0.990 |
Why?
| Biopsy, Needle | 11 | 2017 | 202 | 0.970 |
Why?
| Carcinoma in Situ | 3 | 2008 | 70 | 0.950 |
Why?
| Soybean Proteins | 3 | 2019 | 171 | 0.910 |
Why?
| Obesity | 7 | 2019 | 1111 | 0.880 |
Why?
| Lymph Nodes | 12 | 2017 | 287 | 0.870 |
Why?
| 9,10-Dimethyl-1,2-benzanthracene | 4 | 2015 | 58 | 0.870 |
Why?
| Caseins | 3 | 2019 | 86 | 0.830 |
Why?
| Liver | 8 | 2019 | 1239 | 0.710 |
Why?
| DNA, Neoplasm | 1 | 2018 | 177 | 0.700 |
Why?
| Rats, Zucker | 8 | 2019 | 59 | 0.580 |
Why?
| Uterine Cervical Neoplasms | 3 | 2007 | 278 | 0.580 |
Why?
| Receptor, erbB-2 | 3 | 2018 | 85 | 0.570 |
Why?
| Receptors, Estrogen | 4 | 2018 | 149 | 0.540 |
Why?
| Dietary Supplements | 2 | 2015 | 431 | 0.540 |
Why?
| Arginine | 1 | 2015 | 185 | 0.530 |
Why?
| Aged | 32 | 2018 | 10017 | 0.520 |
Why?
| Neoplasm Staging | 15 | 2015 | 792 | 0.510 |
Why?
| Female | 51 | 2018 | 27910 | 0.490 |
Why?
| Cervical Intraepithelial Neoplasia | 3 | 2007 | 42 | 0.490 |
Why?
| Middle Aged | 34 | 2018 | 13149 | 0.490 |
Why?
| Mammary Neoplasms, Animal | 2 | 2015 | 40 | 0.490 |
Why?
| Isoflavones | 4 | 2017 | 83 | 0.460 |
Why?
| Diet | 2 | 2015 | 583 | 0.460 |
Why?
| Ultrasonography, Mammary | 4 | 2015 | 61 | 0.460 |
Why?
| Dehydroepiandrosterone | 1 | 2010 | 15 | 0.440 |
Why?
| Carcinogens | 3 | 2015 | 238 | 0.430 |
Why?
| Antigens, Tumor-Associated, Carbohydrate | 2 | 2008 | 46 | 0.430 |
Why?
| Benz(a)Anthracenes | 1 | 2010 | 36 | 0.430 |
Why?
| Axilla | 9 | 2017 | 96 | 0.410 |
Why?
| Lymphatic Vessels | 4 | 2014 | 47 | 0.410 |
Why?
| Aged, 80 and over | 15 | 2018 | 3496 | 0.380 |
Why?
| Carcinoma, Ductal | 1 | 2008 | 8 | 0.380 |
Why?
| Plant Lectins | 1 | 2008 | 11 | 0.380 |
Why?
| Adult | 25 | 2018 | 13861 | 0.360 |
Why?
| Prognosis | 11 | 2017 | 2057 | 0.360 |
Why?
| Technetium Tc 99m Sulfur Colloid | 6 | 2014 | 36 | 0.360 |
Why?
| Rats | 14 | 2019 | 3430 | 0.350 |
Why?
| Electrosurgery | 1 | 2007 | 10 | 0.350 |
Why?
| Receptors, Progesterone | 4 | 2018 | 89 | 0.340 |
Why?
| Magnetic Resonance Imaging | 4 | 2014 | 1592 | 0.340 |
Why?
| Lymphedema | 5 | 2017 | 43 | 0.340 |
Why?
| Thinness | 3 | 2017 | 55 | 0.330 |
Why?
| Humans | 47 | 2019 | 50276 | 0.330 |
Why?
| Cytodiagnosis | 4 | 2015 | 43 | 0.320 |
Why?
| Lymphatic Metastasis | 12 | 2015 | 251 | 0.320 |
Why?
| Prospective Studies | 12 | 2017 | 2349 | 0.310 |
Why?
| Nipples | 5 | 2013 | 32 | 0.310 |
Why?
| Combined Modality Therapy | 5 | 2014 | 701 | 0.300 |
Why?
| Adenocarcinoma, Mucinous | 1 | 2005 | 20 | 0.300 |
Why?
| Follow-Up Studies | 10 | 2015 | 2357 | 0.300 |
Why?
| Endometritis | 1 | 2004 | 8 | 0.290 |
Why?
| Ethanol | 5 | 2010 | 322 | 0.280 |
Why?
| Proteoglycans | 1 | 2004 | 96 | 0.280 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2013 | 38 | 0.270 |
Why?
| Animals | 18 | 2019 | 14247 | 0.270 |
Why?
| Radiopharmaceuticals | 6 | 2014 | 252 | 0.270 |
Why?
| Laser Coagulation | 1 | 2003 | 26 | 0.260 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2003 | 86 | 0.260 |
Why?
| Lymph Node Excision | 6 | 2017 | 130 | 0.250 |
Why?
| Carcinoma, Lobular | 3 | 2015 | 33 | 0.250 |
Why?
| Plasma Cells | 1 | 2004 | 225 | 0.250 |
Why?
| Membrane Glycoproteins | 1 | 2004 | 291 | 0.250 |
Why?
| Coloring Agents | 4 | 2014 | 85 | 0.250 |
Why?
| Neoplasm Invasiveness | 5 | 2015 | 294 | 0.250 |
Why?
| Mammaplasty | 2 | 2013 | 41 | 0.240 |
Why?
| Infant Food | 1 | 2002 | 31 | 0.240 |
Why?
| Biopsy, Fine-Needle | 3 | 2015 | 118 | 0.230 |
Why?
| Monitoring, Intraoperative | 3 | 2014 | 67 | 0.220 |
Why?
| Ovarian Neoplasms | 1 | 2005 | 441 | 0.210 |
Why?
| Paraffin Embedding | 2 | 2018 | 57 | 0.210 |
Why?
| Ultrasonography, Interventional | 3 | 2011 | 148 | 0.210 |
Why?
| Immunohistochemistry | 9 | 2017 | 1129 | 0.200 |
Why?
| Lung Neoplasms | 3 | 2015 | 574 | 0.200 |
Why?
| Retrospective Studies | 13 | 2015 | 5676 | 0.200 |
Why?
| Fatty Liver | 2 | 2019 | 125 | 0.200 |
Why?
| Biopsy | 4 | 2007 | 686 | 0.200 |
Why?
| Neoplasm Grading | 3 | 2014 | 131 | 0.200 |
Why?
| Body Weight | 3 | 2017 | 577 | 0.190 |
Why?
| Sensitivity and Specificity | 8 | 2015 | 953 | 0.190 |
Why?
| Adolescent | 8 | 2015 | 6596 | 0.190 |
Why?
| Tissue Fixation | 1 | 2018 | 35 | 0.190 |
Why?
| Specimen Handling | 1 | 2018 | 59 | 0.180 |
Why?
| Alanine Transaminase | 3 | 2015 | 150 | 0.180 |
Why?
| Soybeans | 1 | 2017 | 51 | 0.170 |
Why?
| Pulmonary Medicine | 1 | 2015 | 16 | 0.160 |
Why?
| Protein Hydrolysates | 1 | 2015 | 5 | 0.150 |
Why?
| Aspartate Aminotransferases | 1 | 2015 | 60 | 0.150 |
Why?
| Rats, Sprague-Dawley | 7 | 2015 | 1729 | 0.150 |
Why?
| Kaplan-Meier Estimate | 2 | 2014 | 529 | 0.150 |
Why?
| Treatment Outcome | 5 | 2017 | 5421 | 0.150 |
Why?
| Rosaniline Dyes | 1 | 2014 | 8 | 0.150 |
Why?
| Image-Guided Biopsy | 1 | 2015 | 35 | 0.150 |
Why?
| Sulfotransferases | 1 | 2015 | 49 | 0.140 |
Why?
| Dermatologic Surgical Procedures | 2 | 2013 | 40 | 0.140 |
Why?
| Vacuum | 2 | 2011 | 13 | 0.140 |
Why?
| Plant Extracts | 1 | 2017 | 199 | 0.140 |
Why?
| Melanoma | 2 | 2011 | 303 | 0.140 |
Why?
| Ultrasonography, Doppler | 1 | 2014 | 58 | 0.130 |
Why?
| Interleukin-6 | 1 | 2015 | 299 | 0.130 |
Why?
| Young Adult | 6 | 2015 | 4120 | 0.130 |
Why?
| Carcinoma, Adenoid Cystic | 1 | 2013 | 8 | 0.130 |
Why?
| Intraoperative Care | 2 | 2011 | 63 | 0.130 |
Why?
| Patient Care Planning | 1 | 2013 | 82 | 0.130 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2015 | 422 | 0.130 |
Why?
| Disease-Free Survival | 1 | 2014 | 520 | 0.120 |
Why?
| Preoperative Care | 1 | 2014 | 183 | 0.120 |
Why?
| Lymphography | 1 | 2011 | 10 | 0.120 |
Why?
| Skin Neoplasms | 2 | 2011 | 532 | 0.110 |
Why?
| Image Processing, Computer-Assisted | 2 | 2003 | 279 | 0.110 |
Why?
| Frozen Sections | 1 | 2011 | 16 | 0.110 |
Why?
| Liver Neoplasms | 2 | 2005 | 324 | 0.110 |
Why?
| Cytoprotection | 1 | 2010 | 49 | 0.110 |
Why?
| Fatty Liver, Alcoholic | 1 | 2010 | 8 | 0.110 |
Why?
| DNA Methylation | 1 | 2015 | 572 | 0.100 |
Why?
| Feasibility Studies | 1 | 2011 | 393 | 0.100 |
Why?
| Clinical Competence | 1 | 2013 | 430 | 0.100 |
Why?
| Drug Evaluation, Preclinical | 1 | 2010 | 157 | 0.100 |
Why?
| Genistein | 1 | 2010 | 64 | 0.100 |
Why?
| Cell Line, Tumor | 3 | 2010 | 1472 | 0.100 |
Why?
| Hepatocytes | 2 | 2008 | 207 | 0.100 |
Why?
| Pilot Projects | 1 | 2011 | 766 | 0.090 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1008 | 0.090 |
Why?
| Radionuclide Imaging | 4 | 2011 | 123 | 0.090 |
Why?
| Hepatitis | 1 | 2008 | 21 | 0.090 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2007 | 34 | 0.090 |
Why?
| Protons | 1 | 2007 | 68 | 0.090 |
Why?
| Uterine Cervical Dysplasia | 1 | 2007 | 18 | 0.090 |
Why?
| Male | 9 | 2019 | 27231 | 0.080 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2007 | 70 | 0.080 |
Why?
| Ovariectomy | 1 | 2007 | 128 | 0.080 |
Why?
| Cytokines | 2 | 2008 | 671 | 0.080 |
Why?
| Organ Size | 1 | 2007 | 259 | 0.080 |
Why?
| Oligosaccharides | 1 | 2005 | 41 | 0.080 |
Why?
| Cystadenocarcinoma, Papillary | 1 | 2005 | 16 | 0.080 |
Why?
| Omentum | 1 | 2005 | 17 | 0.080 |
Why?
| Antibodies, Neoplasm | 1 | 2005 | 38 | 0.070 |
Why?
| Uterine Neoplasms | 1 | 2005 | 65 | 0.070 |
Why?
| Monosaccharide Transport Proteins | 1 | 2004 | 16 | 0.070 |
Why?
| Eosine Yellowish-(YS) | 1 | 2004 | 6 | 0.070 |
Why?
| Carcinoma, Small Cell | 1 | 2004 | 26 | 0.070 |
Why?
| Hematoxylin | 1 | 2004 | 8 | 0.070 |
Why?
| Syndecans | 1 | 2004 | 46 | 0.070 |
Why?
| Syndecan-1 | 1 | 2004 | 82 | 0.070 |
Why?
| Endotoxins | 1 | 2004 | 35 | 0.070 |
Why?
| Aging | 1 | 2010 | 740 | 0.070 |
Why?
| Immunoenzyme Techniques | 1 | 2004 | 173 | 0.070 |
Why?
| Endometrium | 1 | 2004 | 72 | 0.070 |
Why?
| Liver Diseases, Alcoholic | 1 | 2004 | 35 | 0.070 |
Why?
| Cytological Techniques | 1 | 2003 | 12 | 0.070 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2004 | 61 | 0.070 |
Why?
| Carbohydrates | 1 | 2004 | 64 | 0.070 |
Why?
| Apoproteins | 1 | 2003 | 11 | 0.070 |
Why?
| Neoplasms | 2 | 2004 | 1143 | 0.070 |
Why?
| Neoplasms, Multiple Primary | 1 | 2003 | 51 | 0.070 |
Why?
| Malondialdehyde | 1 | 2003 | 65 | 0.070 |
Why?
| Dietary Fats | 1 | 2004 | 142 | 0.060 |
Why?
| Fatty Acids | 1 | 2004 | 170 | 0.060 |
Why?
| Overweight | 1 | 2005 | 195 | 0.060 |
Why?
| Aldehydes | 1 | 2003 | 88 | 0.060 |
Why?
| Cytochrome P-450 CYP2E1 | 3 | 2010 | 106 | 0.060 |
Why?
| Cell Membrane | 1 | 2004 | 271 | 0.060 |
Why?
| Surgical Instruments | 1 | 2002 | 44 | 0.060 |
Why?
| Foreign-Body Migration | 1 | 2002 | 34 | 0.060 |
Why?
| Hematoma | 3 | 2010 | 68 | 0.060 |
Why?
| Breast Diseases | 1 | 2002 | 34 | 0.060 |
Why?
| Gene Expression | 2 | 2019 | 701 | 0.060 |
Why?
| Asia | 1 | 2002 | 28 | 0.060 |
Why?
| Risk Factors | 1 | 2011 | 3860 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2008 | 1117 | 0.060 |
Why?
| Chronic Disease | 1 | 2004 | 611 | 0.060 |
Why?
| Cost-Benefit Analysis | 2 | 2015 | 273 | 0.060 |
Why?
| Head and Neck Neoplasms | 1 | 2004 | 302 | 0.050 |
Why?
| Carcinoma, Squamous Cell | 1 | 2004 | 387 | 0.050 |
Why?
| Cytokine Receptor Common beta Subunit | 1 | 2019 | 2 | 0.050 |
Why?
| Neoplasm Metastasis | 2 | 2015 | 258 | 0.050 |
Why?
| Methyltransferases | 1 | 2019 | 40 | 0.050 |
Why?
| Disease Progression | 2 | 2015 | 867 | 0.050 |
Why?
| Health Status | 1 | 2002 | 371 | 0.050 |
Why?
| Alcohol Dehydrogenase | 2 | 2010 | 40 | 0.050 |
Why?
| Time Factors | 1 | 2007 | 3352 | 0.050 |
Why?
| Child, Preschool | 1 | 2008 | 3972 | 0.050 |
Why?
| Cohort Studies | 2 | 2015 | 1444 | 0.050 |
Why?
| Stereotaxic Techniques | 2 | 2010 | 33 | 0.050 |
Why?
| Arm | 2 | 2009 | 50 | 0.050 |
Why?
| Apoptosis | 1 | 2005 | 1313 | 0.050 |
Why?
| Anti-Bacterial Agents | 1 | 2004 | 756 | 0.050 |
Why?
| Polymerase Chain Reaction | 1 | 2019 | 532 | 0.040 |
Why?
| Oxidative Stress | 3 | 2010 | 937 | 0.040 |
Why?
| Injections, Intralesional | 2 | 2008 | 40 | 0.040 |
Why?
| Feces | 1 | 2017 | 135 | 0.040 |
Why?
| Adiponectin | 1 | 2017 | 74 | 0.040 |
Why?
| Risk Assessment | 2 | 2017 | 1387 | 0.040 |
Why?
| Phylogeny | 1 | 2017 | 245 | 0.040 |
Why?
| Reproducibility of Results | 2 | 2015 | 1260 | 0.040 |
Why?
| Child | 1 | 2008 | 6482 | 0.040 |
Why?
| Disease Models, Animal | 2 | 2015 | 1638 | 0.040 |
Why?
| Leptin | 1 | 2017 | 156 | 0.040 |
Why?
| Cost Savings | 1 | 2015 | 73 | 0.040 |
Why?
| Lipid Metabolism | 1 | 2017 | 207 | 0.040 |
Why?
| Protective Agents | 1 | 2015 | 22 | 0.040 |
Why?
| Taxoids | 1 | 2015 | 46 | 0.040 |
Why?
| MCF-7 Cells | 1 | 2015 | 84 | 0.040 |
Why?
| CpG Islands | 1 | 2015 | 106 | 0.040 |
Why?
| Mice, Inbred BALB C | 2 | 2005 | 370 | 0.040 |
Why?
| Infant, Newborn | 1 | 2002 | 2657 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2015 | 190 | 0.030 |
Why?
| Touch | 1 | 2013 | 25 | 0.030 |
Why?
| Insulin | 1 | 2017 | 513 | 0.030 |
Why?
| Tumor Cells, Cultured | 1 | 2015 | 508 | 0.030 |
Why?
| Biopsy, Large-Core Needle | 1 | 2013 | 30 | 0.030 |
Why?
| Neoadjuvant Therapy | 1 | 2015 | 114 | 0.030 |
Why?
| Carcinoma | 1 | 2015 | 152 | 0.030 |
Why?
| Infant | 1 | 2002 | 3499 | 0.030 |
Why?
| Angiogenesis Inhibitors | 1 | 2015 | 211 | 0.030 |
Why?
| Radiotherapy, Adjuvant | 1 | 2013 | 64 | 0.030 |
Why?
| Hormones | 1 | 2013 | 66 | 0.030 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 219 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2013 | 130 | 0.030 |
Why?
| Injections, Intradermal | 1 | 2011 | 15 | 0.030 |
Why?
| X-Rays | 1 | 2011 | 56 | 0.030 |
Why?
| Cicatrix | 1 | 2011 | 38 | 0.030 |
Why?
| Intraoperative Period | 1 | 2011 | 54 | 0.030 |
Why?
| United States | 1 | 2002 | 4825 | 0.030 |
Why?
| Antineoplastic Agents | 2 | 2013 | 1244 | 0.030 |
Why?
| Allyl Compounds | 1 | 2010 | 13 | 0.030 |
Why?
| Sulfides | 1 | 2010 | 31 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 2004 | 1151 | 0.030 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 878 | 0.030 |
Why?
| Chemokines | 1 | 2010 | 95 | 0.030 |
Why?
| Transforming Growth Factor beta1 | 1 | 2010 | 69 | 0.030 |
Why?
| Predictive Value of Tests | 2 | 2004 | 1044 | 0.030 |
Why?
| Survival Rate | 1 | 2012 | 995 | 0.020 |
Why?
| African Americans | 1 | 2015 | 701 | 0.020 |
Why?
| Mammary Glands, Animal | 1 | 2010 | 85 | 0.020 |
Why?
| Double-Blind Method | 1 | 2011 | 733 | 0.020 |
Why?
| Pyrazoles | 1 | 2010 | 118 | 0.020 |
Why?
| Endoplasmic Reticulum | 1 | 2010 | 119 | 0.020 |
Why?
| Cell Division | 1 | 2010 | 366 | 0.020 |
Why?
| Tissue Extracts | 1 | 2007 | 10 | 0.020 |
Why?
| Pregnancy | 1 | 2015 | 2422 | 0.020 |
Why?
| Least-Squares Analysis | 1 | 2007 | 52 | 0.020 |
Why?
| Solubility | 1 | 2007 | 71 | 0.020 |
Why?
| Electrocoagulation | 1 | 2007 | 12 | 0.020 |
Why?
| Biotransformation | 1 | 2007 | 122 | 0.020 |
Why?
| Enteral Nutrition | 1 | 2008 | 131 | 0.020 |
Why?
| Observer Variation | 1 | 2007 | 140 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2010 | 439 | 0.020 |
Why?
| Survival Analysis | 1 | 2009 | 787 | 0.020 |
Why?
| Staining and Labeling | 1 | 2007 | 114 | 0.020 |
Why?
| Positron-Emission Tomography | 1 | 2008 | 311 | 0.020 |
Why?
| E-Selectin | 1 | 2005 | 20 | 0.020 |
Why?
| Body Weights and Measures | 1 | 2005 | 21 | 0.020 |
Why?
| Wheat Germ Agglutinins | 1 | 2005 | 4 | 0.020 |
Why?
| Vaccines, Subunit | 1 | 2005 | 21 | 0.020 |
Why?
| Vaccines, DNA | 1 | 2005 | 23 | 0.020 |
Why?
| Cross Reactions | 1 | 2005 | 55 | 0.020 |
Why?
| Cytotoxicity, Immunologic | 1 | 2005 | 62 | 0.020 |
Why?
| Growth Inhibitors | 1 | 2005 | 31 | 0.020 |
Why?
| Gene Amplification | 1 | 2005 | 57 | 0.020 |
Why?
| Gadolinium | 1 | 2005 | 59 | 0.020 |
Why?
| Ligands | 1 | 2005 | 248 | 0.020 |
Why?
| Glucose Transporter Type 1 | 1 | 2004 | 17 | 0.020 |
Why?
| Sampling Studies | 1 | 2004 | 39 | 0.020 |
Why?
| Free Radicals | 1 | 2004 | 31 | 0.020 |
Why?
| Enzyme Induction | 1 | 2004 | 82 | 0.020 |
Why?
| Corn Oil | 1 | 2004 | 12 | 0.020 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2005 | 273 | 0.020 |
Why?
| Imaging, Three-Dimensional | 1 | 2005 | 174 | 0.020 |
Why?
| MART-1 Antigen | 1 | 2004 | 11 | 0.020 |
Why?
| Eye Neoplasms | 1 | 2004 | 10 | 0.020 |
Why?
| Mice | 2 | 2005 | 6232 | 0.020 |
Why?
| Hyperplasia | 1 | 2004 | 119 | 0.020 |
Why?
| Injections | 1 | 2003 | 63 | 0.020 |
Why?
| Species Specificity | 1 | 2004 | 216 | 0.020 |
Why?
| Necrosis | 1 | 2004 | 196 | 0.020 |
Why?
| Dietary Carbohydrates | 1 | 2004 | 89 | 0.020 |
Why?
| Contrast Media | 1 | 2005 | 233 | 0.020 |
Why?
| Rats, Wistar | 1 | 2004 | 251 | 0.020 |
Why?
| Cytoplasm | 1 | 2004 | 110 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 2005 | 759 | 0.020 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2004 | 166 | 0.020 |
Why?
| Regression Analysis | 1 | 2004 | 468 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2005 | 970 | 0.020 |
Why?
| Energy Intake | 1 | 2004 | 184 | 0.020 |
Why?
| Cell Nucleus | 1 | 2004 | 208 | 0.020 |
Why?
| Cell Proliferation | 1 | 2008 | 1117 | 0.020 |
Why?
| Antigens, Neoplasm | 1 | 2004 | 167 | 0.020 |
Why?
| Sex Characteristics | 1 | 2004 | 193 | 0.020 |
Why?
| Glutathione | 1 | 2004 | 311 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2004 | 678 | 0.020 |
Why?
| Confidence Intervals | 1 | 2002 | 178 | 0.010 |
Why?
| Antioxidants | 1 | 2004 | 294 | 0.010 |
Why?
| Models, Theoretical | 1 | 2002 | 197 | 0.010 |
Why?
| Neoplasm Proteins | 1 | 2004 | 379 | 0.010 |
Why?
| Reoperation | 1 | 2002 | 443 | 0.010 |
Why?
|
|
Korourian's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|